References
- Banham-Hall E, Clatworthy MR, Okkenhaug K. 2012. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J. 6:245–258.
- Bao X, Ma L, He C. 2021. MicroRNA-23a-5p regulates cell proliferation, migration and inflammation of TNF-alpha-stimulated human fibroblast-like MH7A synoviocytes by targeting TLR4 in rheumatoid arthritis. Exp Ther Med. 21(5):479.
- Bheemanaboina RRY. 2020. Isoform-selective PI3K inhibitors for various diseases. Curr Top Med Chem. 20(12):1074–1092.
- Flock G, Baggio LL, Longuet C, Drucker DJ. 2007. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes. 56(12):3006–3013.
- Foster JG, Blunt MD, Carter E, Ward SG. 2012. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev. 64(4):1027–1054.
- Jia H, Dai G, Su W, Xiao K, Weng J, Zhang Z, Wang Q, Yuan T, Shi F, Zhang Z, et al. 2019. Discovery, optimization, and evaluation of potent and highly selective PI3Kgamma-PI3Kdelta dual inhibitors. J Med Chem. 62(10):4936–4948.
- Korfmacher W, Ramanathan R. 2016. HRMS in DMPK. Bioanalysis. 8(16):1635–1637.
- Liu K, Li D, Zheng W, Shi M, Chen Y, Tang M, Yang T, Zhao M, Deng D, Zhang C, et al. 2021. Discovery, optimization, and evaluation of quinazolinone derivatives with novel linkers as orally efficacious phosphoinositide-3-kinase delta inhibitors for treatment of inflammatory diseases. J Med Chem. 64(13):8951–8970.
- Naritomi Y, Sanoh S, Ohta S. 2018. Chimeric mice with humanized liver: application in drug metabolism and pharmacokinetics studies for drug discovery. Drug Metab Pharmacokinet. 33(1):31–39.
- Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Colafrancesco S, Pipi E, Kollert F, Hunter KJ, Brewer C, et al. 2019. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjogren’s syndrome. Ann Rheum Dis. 78(2):249–260.
- Puri KD, Gold MR. 2012. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol. 3:256.
- Que W, Liu H, Yang Q, Xu S. 2018. NK4 inhibits the proliferation and induces apoptosis of human rheumatoid arthritis synovial cells. Cell Biochem Funct. 36(5):273–279.
- Rana AK, Li Y, Dang Q, Yang F. 2018. Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol. 65:348–359.
- Saurina J, Sentellas S. 2019. Liquid chromatography coupled to mass spectrometry for metabolite profiling in the field of drug discovery. Expert Opin Drug Discov. 14(5):469–483.
- Smolen JS, Aletaha D, McInnes IB. 2016. Rheumatoid arthritis. Lancet. 388(10055):2023–2038.
- Sun P, Meng LH. 2020. Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity. Acta Pharmacol Sin. 41(11):1395–1402.
- Weston DJ, Dave M, Colizza K, Thomas S, Tomlinson L, Gregory R, Beaumont C, Pirhalla J, Dear GJ. 2022. A discovery biotransformation strategy: combining in silico tools with high-resolution mass spectrometry and software-assisted data analysis for high-throughput metabolism. Xenobiotica. 52(8):928–942.
- Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, Zhang L. 2021. B cells in rheumatoid arthritis：pathogenic mechanisms and treatment prospects. Front Immunol. 12:750753.
- Zhao J, Jiang P, Guo S, Schrodi SJ, He D. 2021. Apoptosis, autophagy, NETosis, necroptosis, and pyroptosis mediated programmed cell death as targets for innovative therapy in rheumatoid arthritis. Front Immunol. 12:809806.